

# Arati Desai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4717269/publications.pdf>

Version: 2024-02-01

12  
papers

1,301  
citations

1478505

6  
h-index

1474206

9  
g-index

12  
all docs

12  
docs citations

12  
times ranked

2619  
citing authors

#	ARTICLE	IF	CITATIONS
1	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	1,116
2	Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients. <i>Translational Oncology</i> , 2014, 7, 752-758.	3.7	49
3	Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma. <i>NMR in Biomedicine</i> , 2019, 32, e4042.	2.8	38
4	Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2016, 127, 391-400.	2.9	36
5	Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. <i>British Journal of Cancer</i> , 2019, 120, 54-56.	6.4	27
6	Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma. <i>Academic Pathology</i> , 2019, 6, 2374289519848353.	1.1	21
7	ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2018, 20, vi13-vi14.	1.2	6
8	A dual-genotype oligoastrocytoma with histologic, molecular, radiological and time-course features. <i>Acta Neuropathologica Communications</i> , 2020, 8, 115.	5.2	5
9	ACTR-15. SAFETY AND PRELIMINARY ACTIVITY OF PT2385, A FIRST-IN-CLASS HIF2-ALPHA INHIBITOR, PLANNED INTERIM ANALYSIS OF AN OPEN LABEL, SINGLE-ARM PHASE II STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi14-vi14.	1.2	3
10	ATIM-21. UPDATED RESULTS OF A PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2018, 20, vi5-vi5.	1.2	0
11	PATH-40. TARGETED NEXT GENERATION SEQUENCING (NGS) OF YOUNG ADULTS WITH ISOCITRATE-DEHYDROGENASE WILD-TYPE GLIOBLASTOMA (IDH-WT GBM) REVEALS NEGATIVE PROGNOSTIC IMPACT OF EPIDERMAL GROWTH FACTOR RECEPTOR AMPLIFICATION (EGFRAMP). <i>Neuro-Oncology</i> , 2018, 20, vi167-vi167.	1.2	0
12	PATH-41. PLASMA CELL-FREE DNA (cfDNA) CONCENTRATION IS INDEPENDENTLY ASSOCIATED WITH RADIOGRAPHIC TUMOR BURDEN IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PRIOR TO INITIAL SURGICAL RESECTION. <i>Neuro-Oncology</i> , 2018, 20, vi167-vi168.	1.2	0